Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 7, 2023, Shaan Gandhi, M.D., D. Phil., notified the Board of
Directors (the "Board") of DICE Therapeutics, Inc. (the "Company") of his intent
to resign as a Class I director of the Board, as the chair of the Nominating and
Corporate Governance Committee of the Board and as a member of the Audit
Committee of the Board (the "Audit Committee"), effective February 10, 2023 (the
"Resignation"). Such Resignation was not the result of any dispute or
disagreement with the Company or the Board on any matter relating to the
operations, policies or practices of the Company.
In addition, the Board appointed Dr. Jake Simson, an existing member of the
Board, to serve on the Audit Committee, effective upon the Resignation.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
DICE THER 
